Please assess the completion status of the following clinical trial:

Trial Title: Long-term Immunogenicity of a HPV Vaccine in SLE

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~SLE patients~1. Female patients aged 18-35 years~2. Fulfilling the American College of Rheumatology (ACR) criteria for the classification of SLE~3. Having participated in the investigators' original HPV study in 2010~4. Able to give written informed consent~Controls~1. Women aged 18-35 years, matched those of SLE patients recruited~2. No known chronic medical diseases~3. Having participated in our HPV study in 2010

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- SLE patients (Type: None): SLE patients who received HPV vaccination
- Control subjects (Type: None): Healthy subjects who received HPV vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).